In contrast, TP53 mutations seem to be much more predominant in intestinal type adenocarcinomas of the bladder (31 out of 36) than in clear cell adenocarcinomas of the bladder/urethra (1 out of 11). This evidence concerns the gene TP53 and clear cell adenocarcinoma.